Back to search
FDAFDA · Food and drugs·Recall number D-0370-2022

MethylPREDNISolone Acetate Injectable Suspension USP 400 mg/10mL (40mg/mL), 10 mL Multiple-Dose Vial, Rx Only, Manufactured for: Northstar Rx LLC, Memphis, TN 38141, Manufactured By: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, NDC 16714-090-01, packaged in cartons.

Published January 19, 2022 · Recall initiated: December 31, 2021

Summary

FDA records drug Class II recall D-0370-2022, published January 19, 2022 and initiated December 31, 2021. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 7,400 cartons; Lot: Lot # 100022393, exp 09/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA
Distributor
Methylprednisolone, TN Norepinephrine BItartrate - MS, OH
Lot
Lot # 100022393, exp 09/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was MethylPREDNISolone Acetate Injectable Suspension USP 400 mg/10mL (40mg/mL), 10 mL Multiple-Dose Vial, Rx Only, Manufactured for: Northstar Rx LLC, Memphis, TN 38141, Manufactured By: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, NDC 16714-090-01, packaged in cartons. recalled?

Yes. FDA published recall D-0370-2022 on January 19, 2022. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Letter